Version history

{
  "session_id": "sess_SDA-2026-04-01-gap-v2-89432b95",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "claude-sonnet-4",
  "action": "synthesize",
  "content": "```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses\",\n      \"description\": \"Engineering astrocytes with constitutively active AMPK sensors will make them hyperresponsive to neuronal metabolic distress signals, triggering rapid mitochondrial transfer before irreversible neuronal damage occurs. This creates an early-warning system for metabolic neurodegeneration.\",\n      \"target_gene\": \"PRKAA1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.65,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.85,\n        \"therapeutic_potential\": 0.75,\n        \"druggability\": 0.90,\n        \"safety_profile\": 0.70,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.80,\n        \"reproducibility\": 0.75\n      },\n      \"composite_score\": 0.755\n    },\n    {\n      \"title\": \"Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement\",\n      \"description\": \"Targeted near-infrared photobiomodulation will upregulate COX4 activity in astrocytic mitochondria, increasing their ATP production capacity and simultaneously enhancing their motility toward neurons through improved energetics of molecular motors. This non-invasive approach combines energetic enhancement with trafficking stimulation.\",\n      \"target_gene\": \"COX4I1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.55,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.90,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.95,\n        \"safety_profile\": 0.90,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.65\n      },\n      \"composite_score\": 0.685\n    },\n    {\n      \"title\": \"TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking\",\n      \"description\": \"Selective overexpression of TFAM in astrocytes will increase their mitochondrial biogenesis, creating a bioenergetic gradient that drives preferential mitochondrial donation to energy-depleted neurons. This approach amplifies the natural cellular tendency to redistribute healthy mitochondria based on metabolic need.\",\n      \"target_gene\": \"TFAM\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.60,\n        \"therapeutic_potential\": 0.70,\n        \"druggability\": 0.50,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.70\n      },\n      \"composite_score\": 0.650\n    },\n    {\n      \"title\": \"RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery\",\n      \"description\": \"Enhancing RAB27A expression in astrocytes will increase packaging of functional mitochondria into extracellular vesicles, creating a novel delivery mechanism that bypasses the need for direct cell-cell contact. This approach transforms mitochondrial transfer from a contact-dependent to a paracrine-like process.\",\n      \"target_gene\": \"RAB27A\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.45,\n        \"evidence_strength\": 0.40,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.40,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.45\n      },\n      \"composite_score\": 0.520\n    },\n    {\n      \"title\": \"GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer\",\n      \"description\": \"Overexpression of GAP43 in astrocytes will stabilize tunneling nanotubes and increase the efficiency of mitochondrial transfer to metabolically stressed neurons. This approach leverages the cytoskeletal reorganization properties of GAP43 to create more robust intercellular conduits for organelle trafficking.\",\n      \"target_gene\": \"GAP43\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.40,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.30,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.25,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.20,\n        \"data_availability\": 0.45,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.415\n    },\n    {\n      \"title\": \"Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery\",\n      \"description\": \"Engineered fusion proteins combining TRAK1 mitochondrial adaptor domains with enhanced KIF5 motor proteins will create 'super-transporters' that increase the speed and efficiency of mitochondrial movement along astrocytic processes toward neuronal synapses. This synthetic biology approach overcomes natural trafficking limitations.\",\n      \"target_gene\": \"TRAK1_KIF5A\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.35,\n        \"evidence_strength\": 0.30,\n        \"novelty\": 0.90,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.45,\n        \"druggability\": 0.20,\n        \"safety_profile\": 0.30,\n        \"competitive_landscape\": 0.15,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.30\n      },\n      \"composite_score\": 0.355\n    },\n    {\n      \"title\": \"CX43 hemichannel engineering enables size-selective mitochondrial transfer\",\n      \"description\": \"Modified connexin-43 hemichannels with expanded pore diameters will create selective gates that allow mitochondrial passage while maintaining normal gap junction communication. This approach provides controllable, bidirectional organelle transfer through established intercellular communication channels.\",\n      \"target_gene\": \"GJA1\",\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.15,\n        \"evidence_strength\": 0.10,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.10,\n        \"therapeutic_potential\": 0.20,\n        \"druggability\": 0.15,\n        \"safety_profile\": 0.20,\n        \"competitive_landscape\": 0.10,\n        \"data_availability\": 0.25,\n        \"reproducibility\": 0.15\n      },\n      \"composite_score\": 0.225\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source_id\": \"PRKAA1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"AMPK_alpha1\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"AMPK_alpha1\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"energy_sensing_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"energy_sensing_pathway\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"mitochondrial_biogenesis\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"activates\"\n    },\n    {\n      \"source_id\": \"mitochondrial_biogenesis\",\n      \"source_type\": \"pathway\",\n      \"target_id\": \"neurodegeneration\",\n      \"target_type\": \"disease\",\n      \"relation\": \"protects_against\"\n    },\n    {\n      \"source_id\": \"COX4I1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"cytochrome_c_oxidase\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"cytochrome_c_oxidase\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"electron_transport_chain\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"participates_in\"\n    },\n    {\n      \"source_id\": \"TFAM\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"TFAM_protein\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"TFAM_protein\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"mitochondrial_DNA_transcription\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"RAB27A\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"RAB27A_protein\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"RAB27A_protein\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"exocytosis_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"GAP43\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"GAP43_protein\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"GAP43_protein\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"axonal_growth_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"regulates\"\n    },\n    {\n      \"source_id\": \"GJA1\",\n      \"source_type\": \"gene\",\n      \"target_id\": \"connexin43\",\n      \"target_type\": \"protein\",\n      \"relation\": \"encodes\"\n    },\n    {\n      \"source_id\": \"connexin43\",\n      \"source_type\": \"protein\",\n      \"target_id\": \"gap_junction_pathway\",\n      \"target_type\": \"pathway\",\n      \"relation\": \"forms\"\n    }\n  ],\n  \"synthesis_summary\": \"The comprehensive evaluation reveals AMPK hypersensitivity enhancement as the most promising therapeutic approach, achieving the highest composite score (0.755) due to exceptional druggability, established safety profile through metformin precedent, and strong mechanistic rationale. This hypothesis benefits from existing clinical infrastructure, with multiple AMPK modulators in development and the potential for rapid translation through drug repurposing. The photobiomodulation approach ranks second (0.685) as a lower-risk device-based strategy with favorable safety and feasibility profiles, though it faces mechanistic uncertainties and market competition challenges.\\n\\nThe analysis identifies critical knowledge gaps across all hypotheses, particularly regarding the fundamental mechanisms of mitochondrial transfer and the relationship between proposed targets and actual organelle trafficking. The TFAM gradient hypothesis, while mechanistically sound, suffers from moderate druggability and safety concerns related to mitochondrial overproduction. The bottom-ranked hypotheses (connexin engineering, synthetic fusion proteins) face insurmountable physical and biological constraints that make them unsuitable for therapeutic development. The synthesis recommends focusing resources on AMPK modulation with concurrent investment in photobiomodulation as a complementary approach, while establishing robust biomarker systems to measure mitochondrial transfer efficacy in human studies.\"\n}\n```",
  "tokens_used": "2597"
}